NASDAQ:BEAT - BioTelemetry Stock Price, News, & Analysis

$50.66
+0.87 (+1.75 %)
(As of 06/17/2019 04:00 PM ET)
Today's Range
$49.67
Now: $50.66
$51.49
50-Day Range
$47.15
MA: $49.82
$56.93
52-Week Range
$43.30
Now: $50.66
$80.92
Volume336,226 shs
Average Volume590,024 shs
Market Capitalization$1.71 billion
P/E Ratio26.11
Dividend YieldN/A
Beta1.42
BioTelemetry, Inc, a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core lab services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in Healthcare, Research, and Corporate and Other segments. The Healthcare segment focuses on the remote cardiac monitoring to identify arrhythmias or heart rhythm disorders. Read More…

Industry, Sector and Symbol

Industry Specialty outpatient clinics, not elsewhere classified
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BEAT
CUSIPN/A
Phone610-729-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$399.47 million
Cash Flow$3.3483 per share
Book Value$9.32 per share

Profitability

Net Income$42.82 million

Miscellaneous

Employees1,500
Market Cap$1.71 billion
Next Earnings Date7/24/2019 (Estimated)
OptionableOptionable

Receive BEAT News and Ratings via Email

Sign-up to receive the latest news and ratings for BEAT and its competitors with MarketBeat's FREE daily newsletter.

BioTelemetry (NASDAQ:BEAT) Frequently Asked Questions

What is BioTelemetry's stock symbol?

BioTelemetry trades on the NASDAQ under the ticker symbol "BEAT."

How were BioTelemetry's earnings last quarter?

BioTelemetry Inc (NASDAQ:BEAT) released its quarterly earnings results on Thursday, April, 25th. The medical research company reported $0.42 EPS for the quarter, hitting the consensus estimate of $0.42. The medical research company had revenue of $103.98 million for the quarter, compared to analyst estimates of $104.17 million. BioTelemetry had a return on equity of 23.36% and a net margin of 11.86%. BioTelemetry's revenue for the quarter was up 10.0% on a year-over-year basis. During the same period in the previous year, the company posted $0.39 EPS. View BioTelemetry's Earnings History.

When is BioTelemetry's next earnings date?

BioTelemetry is scheduled to release their next quarterly earnings announcement on Wednesday, July 24th 2019. View Earnings Estimates for BioTelemetry.

What guidance has BioTelemetry issued on next quarter's earnings?

BioTelemetry updated its FY 2019 earnings guidance on Thursday, April, 25th. The company provided EPS guidance of for the period. The company issued revenue guidance of $446-450 million, compared to the consensus revenue estimate of $442.05 million.

What price target have analysts set for BEAT?

6 brokers have issued 1 year target prices for BioTelemetry's stock. Their forecasts range from $64.00 to $95.00. On average, they anticipate BioTelemetry's stock price to reach $78.8333 in the next year. This suggests a possible upside of 55.6% from the stock's current price. View Analyst Price Targets for BioTelemetry.

What is the consensus analysts' recommendation for BioTelemetry?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioTelemetry in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioTelemetry.

Has BioTelemetry been receiving favorable news coverage?

Media coverage about BEAT stock has been trending somewhat positive on Monday, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. BioTelemetry earned a news impact score of 1.4 on InfoTrie's scale. They also gave news headlines about the medical research company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the near term. View News Stories for BioTelemetry.

Who are some of BioTelemetry's key competitors?

Some companies that are related to BioTelemetry include Acadia Healthcare (ACHC), Hanger (HNGR), IMAC (IMAC), AAC (AAC) and Biocorrx (BICX).

What other stocks do shareholders of BioTelemetry own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioTelemetry investors own include NVIDIA (NVDA), Adobe (ADBE), Micron Technology (MU), Square (SQ), ABIOMED (ABMD), Alibaba Group (BABA), Veeva Systems (VEEV), Netflix (NFLX), Intuitive Surgical (isrg) and Canopy Growth (CGC).

Who are BioTelemetry's key executives?

BioTelemetry's management team includes the folowing people:
  • Mr. Joseph H. Capper, CEO, Pres & Director (Age 55)
  • Ms. Heather C. Getz, Exec. VP & CFO (Age 44)
  • Mr. Peter F. Ferola, Sr. VP, Gen. Counsel & Sec. (Age 50)
  • Mr. Fred Broadway III, Pres of BioTel Heart (Age 49)
  • Mr. Daniel M. Wisniewski, Sr. VP of Technical Operations (Age 55)

Who are BioTelemetry's major shareholders?

BioTelemetry's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (14.70%), Eagle Asset Management Inc. (1.47%), Carillon Tower Advisers Inc. (1.42%), Stephens Investment Management Group LLC (1.39%), Rothschild & Co. Asset Management US Inc. (0.92%) and Rice Hall James & Associates LLC (0.69%). Company insiders that own BioTelemetry stock include Daniel Wisniewski, Fred Broadway, Heather C Getz, Joseph H Capper, Kirk E Gorman, Peter Ferola, Rebecca W Rimel and Robert J Rubin. View Institutional Ownership Trends for BioTelemetry.

Which major investors are selling BioTelemetry stock?

BEAT stock was sold by a variety of institutional investors in the last quarter, including Kennedy Capital Management Inc., BlackRock Inc., Rice Hall James & Associates LLC, Fiera Capital Corp, THB Asset Management, Columbus Circle Investors, Thompson Siegel & Walmsley LLC and Falcon Point Capital LLC. Company insiders that have sold BioTelemetry company stock in the last year include Daniel Wisniewski, Fred Broadway, Heather C Getz, Joseph H Capper, Kirk E Gorman, Peter Ferola and Robert J Rubin. View Insider Buying and Selling for BioTelemetry.

Which major investors are buying BioTelemetry stock?

BEAT stock was bought by a variety of institutional investors in the last quarter, including Eagle Asset Management Inc., Carillon Tower Advisers Inc., Rothschild & Co. Asset Management US Inc., Meritage Portfolio Management, Raymond James & Associates, WCM Investment Management LLC, Avalon Advisors LLC and Raymond James Financial Services Advisors Inc.. View Insider Buying and Selling for BioTelemetry.

How do I buy shares of BioTelemetry?

Shares of BEAT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BioTelemetry's stock price today?

One share of BEAT stock can currently be purchased for approximately $50.66.

How big of a company is BioTelemetry?

BioTelemetry has a market capitalization of $1.71 billion and generates $399.47 million in revenue each year. The medical research company earns $42.82 million in net income (profit) each year or $1.94 on an earnings per share basis. BioTelemetry employs 1,500 workers across the globe.View Additional Information About BioTelemetry.

What is BioTelemetry's official website?

The official website for BioTelemetry is http://www.gobio.com/.

How can I contact BioTelemetry?

BioTelemetry's mailing address is 1000 Cedar Hollow Road, Malvern PA, 19355. The medical research company can be reached via phone at 610-729-7000 or via email at [email protected]


MarketBeat Community Rating for BioTelemetry (NASDAQ BEAT)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  312 (Vote Outperform)
Underperform Votes:  272 (Vote Underperform)
Total Votes:  584
MarketBeat's community ratings are surveys of what our community members think about BioTelemetry and other stocks. Vote "Outperform" if you believe BEAT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BEAT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/17/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel